Related Experiment Video
Updated: Jan 26, 2026

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
Published on: June 30, 2023
Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: Clinical features and pathophysiology
Takaaki Murakami1, Daisuke Yabe2, Nobuya Inagaki1
1Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Abstract:
It is strongly suggested that dipeptidyl peptidase-4 inhibitors are associated with increased risk of bullous pemphigoid onset, especially in the elderly. Heightened clinical vigilance for bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor use is required in daily diabetes care.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Endocarditis II: Clinical Features of Infective Endocarditis
Pericarditis II: Clinical Features and Diagnostic Tests
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...

